BioNTech SE
BNTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $26.1B
$103.76
▲ +0.86%
P/E
-14.27
Mkt Cap
$26.1B
52-Wk Range
$79.52–$124.00
52-Week Range
$79.52 - $124.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 1.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
2 reasons
- High barriers to entry (70%+ gross margins)
- Established market position
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Positive revenue trend
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+17.8% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying BNTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 2, 2026
AUG 4, 2026
Reported EPS of -$2.58 vs -$2.40 consensus (-7.6% surprise). Revenue of $120.6M vs $180.2M expected (-33.1%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-7.6%
Revenue trend · last 8Q
—
—
-3%
+103%
+22%
-24%
-34%
-60%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.2B
$1.2B
$182.8M
$260.8M
$1.5B
$898.9M
$120.0M
$123.3M
Margins · last 8Q
Gross
—
Operating
—
Profit
-777.3%
Wall Street consensus
8 analysts · 88% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
88%
Hold
13%
Sell
0%
Median Price Target
—
Latest: UBS · $135.00 · May 27, 2026
vs Industry
How BNTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related